

**Androgen receptor pathway activity assay for sepsis diagnosis and prediction of favorable prognosis**

Wilbert Bouwman<sup>1</sup>, Wim Verhaegh<sup>1</sup>, Anja van de Stolpe<sup>2</sup>

<sup>1</sup>Philips Research, Eindhoven, Netherlands, <sup>2</sup>Philips Molecular Pathway Dx, Eindhoven, Netherlands

## Supplementary information (I)




Figure S1: PAS for pathways NFkB, Notch, ER, FOXO, HH, MAPK-AP1, JAK-STAT3 and JAK-STAT1/2 of dataset GSE26440 [1]. Pathway activity score on Y-axis in log<sub>2</sub> odds. Two sided Mann–Whitney–Wilcoxon statistical tests were performed; p-values are indicated in the figures as \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001, \*\*\*\*p < 0.0001 or ns (not significant).




Figure S2: PAS for pathways NFkB, NOTCH, ER, FOXO-PI3K, HH, MAPK-AP1, JAK-STAT3 and JAK-STAT1/2 of dataset GSE26378 [1]. Two sided Mann–Whitney–Wilcoxon statistical tests were performed; p-values are indicated in the figures as \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001, \*\*\*\*p < 0.0001 or ns (not significant).




Figure S3: PAS for pathways NFkB, Notch, ER, FOXO-PI3K, HH, MAPK-AP1, JAK-STAT3 and JAK-STAT1/2 of dataset GSE4607 [2]. Two sided Mann–Whitney–Wilcoxon statistical tests were performed;  $p$ -values are indicated in the figures as  $*p < 0.05$ ,  $**p < 0.01$ ,  $***p < 0.001$ ,  $****p < 0.0001$  or ns (not significant).




Figure S4: PAS for pathways NFkB, Notch, ER, FOXO-PI3K, HH, MAPK-AP1, JAK-STAT3 and JAK-STAT1/2 of dataset GSE13904 [3]. Two sided Mann–Whitney–Wilcoxon statistical tests were performed; p-values are indicated in the figures as \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001, \*\*\*\*p < 0.0001 or ns (not significant).




Figure S5: PAS for pathways NFkB, Notch, ER, FOXO-PI3K, HH, MAPK-AP1, JAK-STAT3 and JAK-STAT1/2 of dataset GSE8121 [4]. Two sided Mann–Whitney–Wilcoxon statistical tests were performed; p-values are indicated in the figures as \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001, \*\*\*\*p < 0.0001 or ns (not significant).




Figure S6: PAS for pathways NFkB, Notch, ER, FOXO-PI3K, HH, MAPK-AP1, JAK-STAT3 and JAK-STAT1/2 of dataset GSE9692 [5]. Two sided Mann–Whitney–Wilcoxon statistical tests were performed; p-values are indicated in the figures as \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , \*\*\*\* $p < 0.0001$  or ns (not significant).




Figure S7: PAS for pathways NFkB, Notch, ER, FOXO-PI3K, HH, MAPK-AP1, JAK-STAT3 and JAK-STAT1/2 of dataset GSE57065 [6]. Two sided Mann–Whitney–Wilcoxon statistical tests were performed; p-values are indicated in the figures as \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , \*\*\*\* $p < 0.0001$  or ns (not significant).






Figure S8: PAS for pathways NFkB, Notch, ER, FOXO-PI3K, HH, MAPK-AP1, JAK-STAT3 and JAK-STAT1/2 of dataset GSE95233 [7]. Two sided Mann–Whitney–Wilcoxon statistical tests were performed; p-values are indicated in the figures as \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , \*\*\*\* $p < 0.0001$  or ns (not significant).




Figure S9: ROC curves for diagnosis of sepsis for pathways NFkB, Notch, TGFβ, ER, FOXO-PI3K, HH, MAPK-AP1, JAK-STAT3 and JAK-STAT1/2. Controls and sepsis patients (sepsis and sepsis shock) from dataset GSE26440 [1], GSE26378 [1], GSE4607 [2], GSE13904 [3], GSE8121[4] and GSE9692 [5] are included.




Figure S10: ROC curves for survival of sepsis for pathways NkKB, Notch, TGF $\beta$ , ER, FOXO-PI3K, HH, MAPK-AP1, JAK-STAT3 and JAK-STAT1/2 sepsis survival and non survival patients from dataset GSE26440 [1], GSE26378 [1], GSE4607 [2], and GSE9692 [5] are included.




Figure S11: PAS of day 1 versus day 3 of sepsis survival and non-survival patients for pathways

*NFκB, Notch, TGFβ, ER, FOXO-PI3K, HH, MAPK-AP1, JAK-STAT3 and JAK-STAT1/2. Dataset*

*GSE95233 [7].*




Figure S12: AR pathway activity analysis of dataset GSE161731 [8] of whole blood samples from patients presenting to the emergency department with acute respiratory infection caused by influenza (virus), or bacterial pneumonia and matched healthy controls. RNAseq data were analyzed with our signal transduction pathway assays converted to RNAseq as input data. *Two sided Mann–Whitney–Wilcoxon statistical tests is performed; p-values are indicated in the figures.*

Dataset	Sample type	Sample prep	Population information	GSM numbers of removed duplicates	Pubmed
GSE26440	blood samples were obtained within 24 hours of initial presentation to the PICU with septic shock	Whole blood and PaxGene™ Blood RNA System	Children =10 years of age admitted to the pediatric intensive care unit (PICU) and meeting pediatric-specific criteria for septic shock were eligible for enrollment	GSM648594 GSM648650 GSM648652 GSM648653 GSM648657 GSM648675 GSM648680 GSM648719	<a href="https://pubmed.ncbi.nlm.nih.gov/">https://pubmed.ncbi.nlm.nih.gov/</a>
GSE26378	blood samples were obtained within 24 hours of initial presentation to the PICU with septic shock	Whole blood and PaxGene™ Blood RNA System	Children =10 years of age admitted to the pediatric intensive care unit (PICU) and meeting pediatric-specific criteria for septic shock were eligible for enrollment	GSM647621	<a href="https://pubmed.ncbi.nlm.nih.gov/">https://pubmed.ncbi.nlm.nih.gov/</a>
GSE4607	Blood samples were obtained within 24 hours of admission to the PICU, heretofore referred to as "Day 1" of septic shock.	Whole blood and PaxGene™ Blood RNA System	Children < 10 years of age admitted to the pediatric intensive care unit (PICU) and meeting criteria for septic shock were eligible for the study. Septic shock was defined using pediatric-specific criteria		<a href="https://pubmed.ncbi.nlm.nih.gov/">https://pubmed.ncbi.nlm.nih.gov/</a>
GSE13904	blood samples were obtained on day 1 of the study and when possible on day 3 of the study. Day 1 of the study was defined as within the first 24 hours of meeting criteria for a given study category in any PICU patient, whether at admission to the PICU or after initial admission to the PICU with a nonstudy-related classification. Day 3 of the study was defined as 48 hours after drawing day 1 samples, regardless of the PICU status.	Whole blood and PaxGene™ Blood RNA System	Children ≤10 years of age admitted to the pediatric intensive care units (PICUs) and meeting published, pediatric-specific criteria for SIRS, sepsis, or septic shock were eligible	GSM350141 GSM350142 GSM350144 GSM350145 GSM350146 GSM350147 GSM350154 GSM350209 GSM350238 GSM350239 GSM350246 GSM350248 GSM350249 GSM350257 GSM350262 GSM350267 GSM350268 GSM350271 GSM350272 GSM350273 GSM350274 GSM350275 GSM350279	<a href="https://pubmed.ncbi.nlm.nih.gov/">https://pubmed.ncbi.nlm.nih.gov/</a>

				GSM350286 GSM350291 GSM350293 GSM350294 GSM350297 GSM350298 GSM350299 GSM350300 GSM350302 GSM350303 GSM350304 GSM350309 GSM350310 GSM350316 GSM350317 GSM350325 GSM350326 GSM350343 GSM350344 GSM350347 GSM350348 GSM350350 GSM350351 GSM350358 GSM350363	
GSE8121	<p>Blood samples for RNA isolation were obtained within 24 h of admission to the PICU, heretofore called "day one" of septic shock. An additional sample was obtained for RNA isolation 48 hours after obtaining the day one sample ("day three" of septic shock).</p>	<p>Whole blood and PaxGene™ Blood RNA System</p>	<p>Children &lt; ten years of age admitted to the PICU and meeting criteria for septic shock were eligible for the study</p>	GSM201231 GSM201241 GSM201242 GSM201245 GSM201246 GSM201251 GSM201252 GSM201254 GSM201256 GSM201259 GSM201261 GSM201262 GSM201263 GSM201265 GSM201268 GSM201270 GSM201272 GSM201273 GSM201281 GSM201282	<a href="https://pubmed.ncbi.nlm.nih.gov/">https://pubmed.ncbi.nlm.nih.gov/</a>

				GSM201283 GSM201286 GSM201291 GSM201292 GSM201295 GSM201297 GSM201299 GSM201301	
GSE9692	blood samples for RNA isolation were obtained within 24 hours of admission to the PICU, heretofore referred to as "day 1" of septic shock.	Whole blood and PaxGene™ Blood RNA System	Children < 10 years of age admitted to the pediatric intensive care unit (PICU), and meeting pediatric-specific criteria for septic shock were eligible for the study	GSM244479 GSM244483 GSM244484 GSM244486 GSM244490 GSM244491 GSM244492 GSM244497 GSM244504 GSM244507	<a href="https://pubmed.ncbi.nlm.nih.gov/">https://pubmed.ncbi.nlm.nih.gov/</a>
GSE57065	Blood samples were collected within 30 min and 24 and 48 h after shock.	Whole blood and PaxGene™ Blood RNA System	18 years and above were enrolled at the onset of septic shock.		<a href="https://pubmed.ncbi.nlm.nih.gov/">https://pubmed.ncbi.nlm.nih.gov/</a>
GSE95233	Septic shock patients were sampled twice, at admission, and a second time at D2 or D3.	Whole blood and PaxGene™ Blood RNA System	Septic shock patients (adults) admitted to the Intensive Care Unit (ICU) were compared to healthy volunteers, and according to day 28 survival status.		<a href="https://pubmed.ncbi.nlm.nih.gov/">https://pubmed.ncbi.nlm.nih.gov/</a>
GSE161731	whole blood samples from patients presenting to the emergency department with acute respiratory infection caused by influenza (virus), or bacterial pneumonia and matched healthy controls	Whole blood and PaxGene™ Blood RNA System	Patients presenting to the emergency department with acute respiratory infections		<a href="https://pubmed.ncbi.nlm.nih.gov/">https://pubmed.ncbi.nlm.nih.gov/</a>

**Supplementary Table 1:** Public clinical datasets from the GEO database used in used in study.



	Healthy controls Children (log2 odds scores)			
<b>Pathway</b>	<b>Mean</b>	<b>SD</b>	<b>Mean + 1 SD</b>	<b>Mean + 2 SD</b>
MAPK-AP1	-9.67	1.73	-7.94	-6.20
AR	-15.37	1.52	-13.85	-12.33
ER	-18.22	1.10	-17.12	-16.02
HH*	-13.86	1.45	-15.31	-16.76
NFκB	1.49	3.01	4.50	7.51
Notch	-5.61	1.78	-3.84	-2.06
FOXO-PI3K	5.12	3.33	8.45	11.77
JAK-STAT1/2	-5.54	2.34	-3.20	-0.86
JAK-STAT3	-7.86	2.00	-5.86	-3.85
TGFβ	-17.05	1.63	-15.42	-13.79

	Healthy controls Adults (log2 odds scores)			
<b>Pathway</b>	<b>Mean</b>	<b>SD</b>	<b>Mean + 1 SD</b>	<b>Mean + 2 SD</b>
MAPK-AP1	-8.04	0.94	-7.10	-6.16
AR	-12.44	1.44	-11.01	-9.57
ER	-15.53	1.88	-13.65	-11.77
HH*	-12.51	1.73	-10.78	-9.04
NFκB	4.29	3.50	7.79	11.29
Notch	-4.74	1.62	-3.12	-1.50
FOXO-PI3K	8.49	3.22	11.70	14.92
JAK-STAT1/2	-5.59	3.12	-2.47	0.65
JAK-STAT3	-1.61	1.54	-0.07	1.47
TGFβ	-13.01	1.83	-11.18	-9.35

	Healthy controls Children + Adults (log2 odds scores)			
<b>Pathway</b>	<b>Mean</b>	<b>SD</b>	<b>Mean + 1 SD</b>	<b>Mean + 2 SD</b>
MAPK-AP1	-9.21	1.71	-7.49	-5.78
AR	-14.54	2.00	-12.54	-10.54
ER	-17.46	1.83	-15.63	-13.80
HH*	-13.48	1.65	-15.13	-16.77
NFκB	2.29	3.39	5.68	9.06
Notch	-5.36	1.77	-3.59	-1.82

FOXO-PI3K	6.08	3.62	9.70	13.32
JAK-STAT1/2	-5.56	2.57	-2.98	-0.41
JAK-STAT3	-6.08	3.40	-2.69	0.71
TGF $\beta$	-15.90	2.49	-13.41	-10.92

**Supplementary Table 2:** Mean plus 1 and 2 SD of pathway activity scores in healthy children (n=93; GSE26440, GSE26378, GSE4607, GSE9692, GSE8121 and GSE13904) and adults (n=37; GSE57065 and GSE95233). \*for HH mean minus SD.

T-test one sided	Survivors day 1 vs day 3			Non survivors day 1 vs day 3		
	paired			paired		
	p-value	significance	numbers day 1 / day 3	p-value	significance	numbers day 1 / day 3
MAPK-AP1	0.37	-	17/17	0.82	-	8/8
AR	0.19	-	17/17	0.06	-	8/8
ER	0.36	-	17/17	0.73	-	8/8
FOXO-PI3K	0.23	-	17/17	0.85	-	8/8
HH	0.67	-	17/17	0.79	-	8/8
NFκB	0.57	-	17/17	0.92	-	8/8
Notch	0.57	-	17/17	0.67	-	8/8
JAK-STAT1/2	0.06	-	17/17	0.93	-	8/8
JAK-STAT3	0.58	-	17/17	0.73	-	8/8
TGFβ	0.40	-	17/17	0.61	-	8/8

T-test one sided	Survivors day 1 vs day 3			Non survivors day 1 vs day 3		
	unpaired			unpaired		
	p-value	significance	numbers day 1 / day 3	p-value	significance	numbers day 1 / day 3
MAPK-AP1	0.12	-	31/19	0.74	-	15/9
AR	0.03	*	31/19	0.31	-	15/9
ER	0.24	-	31/19	0.41	-	15/9
FOXO-PI3K	0.11	-	31/19	0.79	-	15/9
HH	0.79	-	31/19	0.67	-	15/9
NFκB	0.43	-	31/19	0.60	-	15/9
Notch	0.50	-	31/19	0.79	-	15/9
JAK-STAT1/2	0.09	-	31/19	0.62	-	15/9
JAK-STAT3	0.44	-	31/19	0.66	-	15/9
TGFβ	0.05	-	31/19	0.49	-	15/9

**Supplementary Table 3:** Paired and unpaired one sided t-test for survivors and non survivors day 1 vs

day 3 from dataset GSE95233. \* $p < 0.05$ , \*\* $p < 0.01$ , - not significant.

	Mean							
	Children						Adults	
Pathway	GSE4607	GSE26440	GSE8121	GSE9692	GSE13904	GSE26378	GSE57065	GSE95233
MAPK-AP1	-9.8	-10.1	-9.6	-9.3	-9.5	-9.1	-8.3	-7.5
AR	-15.3	-15.2	-15.3	-15.3	-15.7	-15.6	-13.1	-11.0
ER	-18.4	-18.6	-18.4	-18.0	-18.7	-17.0	-16.6	-13.3
HH	-13.6	-14.2	-13.4	-13.3	-13.6	-14.4	-13.4	-10.6
NFκB	0.8	1.0	1.0	2.0	1.0	3.4	6.0	0.8
Notch	-5.1	-5.9	-5.1	-5.0	-6.2	-5.9	-4.3	-5.7
FOXO-PI3K	4.9	4.9	4.6	5.1	5.1	6.1	10.2	5.0
JAK-STAT1/2	-5.7	-5.6	-5.5	-5.6	-5.8	-5.0	-5.4	-5.9
JAK-STAT3	-7.7	-7.5	-8.1	-8.2	-8.1	-8.3	-2.1	-0.6
TGFβ	-17.0	-17.4	-17.1	-16.6	-16.8	-16.8	-13.2	-12.6

	SD							
	Children						Adults	
Pathway	GSE4607	GSE26440	GSE8121	GSE9692	GSE13904	GSE26378	GSE57065	GSE95233
MAPK-AP1	1.9	2.0	1.7	1.5	1.2	1.5	0.8	1.0
AR	1.4	1.8	1.2	1.3	1.3	1.7	1.2	0.6
ER	0.9	1.1	0.9	0.9	1.0	0.8	1.1	1.2
HH	1.5	1.4	1.6	1.8	1.6	1.0	1.2	0.9
NFκB	3.2	3.1	3.3	3.3	2.5	1.8	1.9	3.5
Notch	2.0	1.6	1.5	1.6	2.0	1.5	1.4	1.6
FOXO-PI3K	1.1	2.6	1.2	1.3	1.3	2.4	2.2	1.9
JAK-STAT1/2	1.9	2.3	1.8	2.0	2.1	1.5	3.8	0.7
JAK-STAT3	1.6	1.6	1.4	1.0	1.3	2.3	1.5	1.2
TGFβ	3.0	3.1	2.3	2.2	3.1	3.1	2.1	1.2

**Supplementary Table 4:** Mean and standard deviation PAS of each dataset including healthy children and adults.

Sepsis diagnosed	sepsis confirmed	No sepsis	
Test positive	308	3	311
Test negative	91	90	181
	399	93	492

Sensitivity	77%
Specificity	97%
Positive prediction value (PPV)	99%
Negative prediction value (NPV)	50%
Fisher's Exact Test	p-value < 2.2e-16

Dying from sepsis	sepsis nonsurvival	sepsis survival	
Test positive	42	157	199
Test negative	3	53	56
	45	210	255

Sensitivity	93%
Specificity	25%
Positive prediction value (PPV)	21%
Negative prediction value (NPV)	95%
Fisher's Exact Test	p-value = 0.005023

Surviving sepsis	sepsis survival	sepsis non survival	
Test positive (below threshold)	53	3	56
Test negative (above threshold)	157	42	199
	210	45	255

Sensitivity	25%
Specificity	93%
Positive prediction value (PPV)	95%
Negative prediction value (NPV)	21%
Fisher's Exact Test	p-value = 0.005023

**Supplementary table 6: TGFβ sensitivity, specificity, PPV and NPV.**

Sepsis diagnosed	sepsis confirmed	No sepsis	
Test positive	254	2	256
Test negative	145	91	236
	399	93	492

Sensitivity	64%
Specificity	98%
Positive prediction value (PPV)	99%
Negative prediction value (NPV)	39%
Fisher's Exact Test	p-value < 2.2e-16

Dying from sepsis	sepsis nonsurvival	sepsis survival	
Test positive	31	142	173
Test negative	14	68	82
	45	210	255

Sensitivity	69%
Specificity	32%
Positive prediction value (PPV)	18%
Negative prediction value (NPV)	83%

Surviving sepsis	sepsis survival	sepsis non survival	
Test positive (below threshold)	68	14	82
Test negative (above threshold)	142	31	173
	210	45	255

Fisher's Exact Test p-value = 1

Sensitivity 32%

Specificity 69%

Positive prediction value (PPV) 83%

Negative prediction value (NPV) 18%

Fisher's Exact Test p-value = 1

**Supplementary table 5: AR pathway assay for sepsis diagnosis and prognosis: sensitivity, specificity, PPV and NPV.**

## References:

- [1] J. L. Wynn *et al.*, "The influence of developmental age on the early transcriptomic response of children with septic shock," *Mol Med*, vol. 17, no. 11–12, pp. 1146–1156, 2011, doi: 10.2119/molmed.2011.00169.
- [2] H. R. Wong *et al.*, "Genome-level expression profiles in pediatric septic shock indicate a role for altered zinc homeostasis in poor outcome," *Physiol Genomics*, vol. 30, no. 2, pp. 146–155, Jul. 2007, doi: 10.1152/physiolgenomics.00024.2007.
- [3] H. R. Wong *et al.*, "Genomic expression profiling across the pediatric systemic inflammatory response syndrome, sepsis, and septic shock spectrum," *Crit Care Med*, vol. 37, no. 5, pp. 1558–1566, May 2009, doi: 10.1097/CCM.0b013e31819fcc08.
- [4] T. P. Shanley *et al.*, "Genome-Level Longitudinal Expression of Signaling Pathways and Gene Networks in Pediatric Septic Shock," *Mol Med*, vol. 13, no. 9–10, pp. 495–508, 2007, doi: 10.2119/2007-00065.Shanley.
- [5] N. Cvijanovich *et al.*, "Validating the genomic signature of pediatric septic shock," *Physiol Genomics*, vol. 34, no. 1, pp. 127–134, Jun. 2008, doi: 10.1152/physiolgenomics.00025.2008.
- [6] M.-A. Cazalis *et al.*, "Early and dynamic changes in gene expression in septic shock patients: a genome-wide approach," *Intensive Care Med Exp*, vol. 2, no. 1, p. 20, Dec. 2014, doi: 10.1186/s40635-014-0020-3.
- [7] F. Venet *et al.*, "Modulation of LILRB2 protein and mRNA expressions in septic shock patients and after ex vivo lipopolysaccharide stimulation," *Hum Immunol*, vol. 78, no. 5–6, pp. 441–450, Jun. 2017, doi: 10.1016/j.humimm.2017.03.010.
- [8] M. T. McClain *et al.*, "Dysregulated transcriptional responses to SARS-CoV-2 in the periphery," *Nature Communications*, vol. 12, no. 1, Art. no. 1, Feb. 2021, doi: 10.1038/s41467-021-21289-y.